Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-γ.

@article{Viaud2011UpdatedTT,
  title={Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-γ.},
  author={Sophie Viaud and St{\'e}phanie Ploix and Val{\'e}rie Lapierre and Clotilde Th{\'e}ry and P H Comm{\`e}re and Dominique Tramalloni and Kevin Gorrichon and Pauline Virault-Rocroy and Thomas Tursz and Olivier Lantz and Laurence Zitvogel and Nathalie Chaput},
  journal={Journal of immunotherapy},
  year={2011},
  volume={34 1},
  pages={65-75}
}
Dendritic cell-derived exosomes (Dex) are nanovesicles bearing major histocompatibility complexes promoting T-cell-dependent antitumor effects in mice. Two phase I clinical trials aimed at vaccinating cancer patients with peptide-pulsed Dex have shown the feasibility and safety of inoculating clinical-grade Dex, but have failed to show their immunizing capacity. These low immunogenic capacities have led us to develop second-generation Dex with enhanced immunostimulatory properties. Here, we… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

Similar Papers

Loading similar papers…